Best Life Sciences Platforms and Tools Companies in Singapore
The 59 best Life Sciences Platforms and Tools companies in Singapore in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MEGAROBO.
Singapore's Life Sciences Platforms and Tools sector has 59 tracked companies and $780M in disclosed funding behind them. That's the starting number. This directory ranks the best Life Sciences Platforms and Tools companies in Singapore by disclosed equity funding and recent funding momentum, and the spread here is genuinely worth your attention. Megarobo leads at $427M raised, Esco Lifesciences follows at $200M, and Engine Biosciences has pulled in $86M. Three companies alone account for the bulk of that $780M pool, which tells you something about how concentrated the capital story really is.
The global market context sharpens the picture. The sector was valued at roughly $89.4B in 2020 and is forecast to reach $183.8B by 2027, compounding at 10.8% annually, driven by advances in quantitative accuracy, MS resolution, and information sciences. Regulatory challenges remain a structural friction point, slowing commercialization timelines for platform-stage companies. I'd note that SEEDS Capital and EDBI are the most active backers here, which reflects Singapore's deliberate public-sector push into life sciences infrastructure. One unicorn among 59 companies suggests the market's still in its build phase. The upside is real, but so is the patience required.
- ResearchAndMarkets.com
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Singapore
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MEGAROBO 🦄 Provider of robotic solutions for industrial laboratory automation 53Moat top 15%Funding top 29%Talent top 38%Global top 44% All 8 signals ▾Moattop 15% Fundingtop 29% Talenttop 38% Globaltop 44% Growthtop 45% Markettop 49% Techbottom 35% Newsbottom 22% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $427M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $427M | 48 mo ago | Series C | Daniel Huang Co-Founder | 2016 | PHPBootstrapTengine+7 | — | 1 partnership · 1 award |
| 2 | Esco Lifesciences Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools | $200M | 61 mo ago | Late Stage | Estelle Couriol Founder & Creative director ESCO | 1978 | SalesforcePHPCentOS+25 | — | 1 expansion |
| 3 | Engine Biosciences Developer of platform technology for combinatorial genetics discovery | $86M | 32 mo ago | Series A | Jeffrey Lu Co-Founder And Ceo | 2014 | WordPressMySQLPHP+20 | 31 patents PKMYT1 kinase inhibitors, tau-modulating agents, and synthetic‑lethality cancer therapeutics | — |
| 4 | Galatek Developer of automation solutions for life science and semiconductor industries | $30M | 6 mo ago | Series A | David Tian Founder & CEO | 2025 | PHPanime.jsLayui+12 | — | 1 expansion |
| 5 | Allozymes Developer of enzyme engineering platform for biosolutions across diverse industries | $20M | 26 mo ago | Series A | Akbar Vahidi Co-Founder & CTO | 2019 | WebflowYouTubeSwiper+14 | — | — |
| 6 | Cordlife Provider of cord blood and cord lining banking and newborn metabolic screening | $7M | 272 mo ago | Public | — | 2001 | DrupalPHPUbuntu+14 | — | — |
| 7 | CellResearch Developer of stem cell based research products and cosmeceuticals | $6M | 125 mo ago | Series A | Phan Thang Co-Founder | 2002 | Squarespace CommerceSquarespaceTypeScript+13 | — | — |
| 8 | Cellivate Technologies Developer of nanotechnology to study issues related to growing cells 11Moat top 48%Talent bottom 49%Funding bottom 48%Global bottom 37% All 6 signals ▾Moattop 48% Talentbottom 49% Fundingbottom 48% Globalbottom 37% Marketbottom 24% Newsbottom 18% Moat: Editorial + unicorn rating 4/10 · 8 curated direct competitors tracked Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $2M | 14 mo ago | Seed | Viknish Krishnan-Kutty Founder & CEO | 2019 | — | — | — |
| 9 | Craft Health Provider of 3D printed personalized pharmaceuticals and nutraceuticals with end-to-end solutions | $1M | 25 mo ago | Series A | Wei Goh Co-Founder & CEO | 2019 | — | 11 patents 3D‑printed oral dosage forms enabling extended and colon‑targeted drug release | — |
| 10 | Vela Diagnostics Developer of integrated molecular solutions for the diagnosis of infectious diseases and cancer | $225K | 74 mo ago | Acquired | — | 2011 | Cart FunctionalityContaoSalesforce+7 | — | — |
| 11 | Biopsin Developer of real-time microbial detection system | $175K | 89 mo ago | Seed | Sheetal Sinha Co-Founder & CTO | 2018 | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Singapore
#1
Series A · Singapore, Singapore · founded 2025$30Mraised▾
Developer of automation solutions for life science and semiconductor industries. The company provides liquid handling workstations, high content cell imaging systems, and three-dimensional disease model technology. It also offers precision motion control, advanced optics, and artificial intelligence vision platforms. The company focuses on cell gene editing, high-throughput drug screening, and synthetic biology.
- Dec 2025Series A$30M
#2
Seed · Singapore, Singapore · founded 2019 · 8 employees$2Mraised▾
Developer of nanotechnology to study issues related to growing cells. It offers a product called ProCYTE, which is designed to improve cell growth and adhesion. It caters to biotechnology.
- Apr 2025Seed—
- Jan 2025Seed$17.5K
- Aug 2024Seed$1M
- May 2023Seed$1M
#3
MEGAROBO 🦄Series C · Singapore, Singapore · founded 2016$427.3Mraised▾
Provider of robotic solutions for industrial laboratory automation. It leverage robotics and AI technologies to enhace productivity and productivity in various life sciences applications, including drug discovery and clinical diagnostics. It provides solutions for throughput drug screening, automated cell line development, and synthetic biology.
- Jun 2022Series C$300M
- May 2021Series B$65M
- Feb 2021Series B$30M
- Nov 2020Series B$30M
#4
Series A · Singapore, Singapore · founded 2014 · 39 employees$86Mraised▾
Developer of platform technology for combinatorial genetics discovery. The company's platform technology for the discovery of novel gene and drug combinations for therapeutic and industrial biotechnology applications. The company's technology allows for ultra-high-throughput screens and the discovery of combinatorial genes and drugs with effects on targeted phenotypes.
- Oct 2023Series A$27M
- May 2021Series A$43M
- Jan 2018Seed$10M
#5
Series A · Singapore, Singapore · founded 2019 · 22 employees$20Mraised▾
Developer of enzyme engineering platform for biosolutions across diverse industries. The platform utilizes microfluidics technology for high-throughput screening of enzyme variants. It offers services for enzyme engineering projects, from in-silico study to supply. The company also provides licensing terms for biosolutions development and database access for enzyme design.
- May 2024Series A$15M
- Aug 2023Series A—
- Jul 2021Seed$5M
- 2019Seed—
#6
Late Stage · Singapore, Singapore · founded 1978 · 5 employees$200Mraised▾
Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools. Its portfolio includes cell culturing reagents , monitoring systems, incubators, hoods,and others. It also offers installation and maintenance srvices to life science inductries.
#7
Series A · Singapore, Singapore · founded 2019 · 9 employees$1Mraised▾
Provider of 3D printed personalized pharmaceuticals and nutraceuticals with end-to-end solutions. It offers customized approaches to drug delivery, from research and development to manufacturing. The company provides hardware, software, and formulation integration for mass customization. Varied dosage forms such as tablets, beads, and gummies are manufactured in a HEPA filtered clean environment, from prototyping to pilot batch.
- May 2024Series A—
- Seed$1M
#8
Public · Singapore, Singapore · founded 2001 · 111 employees$7Mraised▾
Provider of cord blood and cord lining banking and newborn metabolic screening. The company offers a range of services, including cord blood banking, cord lining and cord tissue banking, as well as diagnostics services such as non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening.
- Nov 2003Series B$7M
#9
Series A · Singapore, Singapore · founded 2002$5.9Mraised▾
CellResearch Corp develops stem-cell-based research products and therapeutics. Its product offerings include epithelial and mesenchymal stem cells obtained from cord blood for research. The products developed are called Calecim which is a cosmeceutical formulation for skin rejuvenation. The company also provides a cord blood banking service and a global cord registry. The company also holds 40 patents for its products.
- Feb 2016Series A$5.9M
#10
Acquired · Singapore, Singapore · founded 2011 · 200 employees$225Kraised▾
Developer of integrated molecular solutions for the diagnosis of infectious diseases and cancer. The company is a pioneer in offering both PCR and Next-Generation Sequencing platforms to test for infectious diseases and oncologic targets. The company's product line includes Sentosa SX101, Rotor-Gene Q, labware, consumables, and PCR reagents.
- Apr 2020Grant (prize money)$225K
#11
Seed · Singapore, Singapore · founded 2018$175Kraised▾
Developer of real-time microbial detection system
#12
Deadpooled · Singapore, Singapore · founded 1999$41Kraised▾
Bio-Scaffold develops biocompatible 3D printed implants for tissue engineering applications. Its first product Alvelac is a small porous cylindrical biopolymer that is placed at the tooth extraction site for the preservation of the alveolar ridge. The biopolymer biodegrades in 2-6 months of insertion. Its products are FDA approved and CE marked. The company has partnered with A*STAR, Singapore for strategic research and with NUS, Singapore for clinical research. It has secured exclusive rights for the commercial use of its technology in oral and maxillofacial applications.
- Grant (prize money)$41K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Singapore
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 631 Singapore-affiliated papers.
- Ministry of Education187
- National University of Singapore111
- Agency for Science, Technology and Research58
- Nanyang Technological University56
- Duke-NUS Medical School45
- Genome4→22
- Transcriptome1→18
- Gene6→17
- Genomics1→10
- Cancer1→9
- Transcriptome1→12
- Cancer2→10
- Drug1→4
- Microbiome1→4
- Disease1→19
Where bioinformatics is researched across Singapore
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.